Featured Lab/Clients

NeoGenomics is a premier cancer diagnostic, pharma services, and information services company, helping patients get the right testing for their cancer and helping in the pursuit of providing better futures for people living with cancer. NeoGenomics Laboratories has been serving patients for over 18 years, developing and delivering laboratory diagnostic and clinical trial services with a focus on cancer.

Billion To One is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. Billion To One work to improve disease detection by counting molecules with their proprietary molecular counting platform. Billion To One place patients at the forefront of everything Billion To One does. Billion To One are currently applying our proprietary technology to non-invasive prenatal screening and liquid biopsy.

Boston Heart offers novel diagnostics that drive reports with color coded test results, interpretations and clinical treatment considerations that help characterize risk, develop insight and communicate more reflectively with patients. Boston Heart’s diagnostic report communicates test results into actionable, individualized and easy-to-understand steps which improves patient engagement, health literacy and adherence to treatment plans.

OneTest is a cutting-edge Multi-cancer Early Detection (MCED) test dedicated to aiding in the early detection of cancer. Since 2017, 2020 GeneSystems has been specializing in cancer screening that helps identify cancer in its early stages using tumor biomarkers. Their proprietary technology, OneTest, employs a patented cancer screening approach developed using machine-learning software and real-world cancer studies from around the world.

Smart Health Diagnostics Company™ develops precision diagnostics that address unmet clinical needs in vascular, metabolic, and oncological diseases. They assess physical wellbeing and detect problems with accurate and actionable lab results. Smart Health is a CLIA-certified and CAP-accredited lab with clinically-validated tests. SmartVascular Dx™ (formerly PULS) helps determine the potential risk of heart attacks and strokes for patients up to five years out of the potential event. SmartHealth Dx testing is performed by MorningStar Laboratories.

PlexusDx is a fast-growing, CLIA-certified laboratory specializing in precision health that offers advanced genetic analysis and personalized insights. Combining genomics, clinical expertise, and AI, PlexusDx provides science-based recommendations tailored to each individual's genetic predispositions. We are committed to delivering a comprehensive, clinician-focused experience. Beyond test results, PlexusDx offers detailed interpretations, actionable recommendations, and 1-on-1 consultations by licensed phlebotomists and dietitians. For laboratories seeking to expand, PlexusDx provides a seamless, cost-effective solution. Partner labs can leverage PlexusDx's advanced testing infrastructure and scientific expertise to offer complex PGx services under their brand, without investing in specialized equipment or training.

Sarana Health delivers an integrated, whole-body care and wellness program based on advanced testing, and proven science. Please visit info.sarana.health to learn more about their Early Adopters program.

Naveris Inc. is a molecular diagnostics company developing and commercializing novel blood and saliva tests to enhance the early detection and management of viral-associated cancers. The company’s NavDx® blood test, which uses proprietary technology to detect tumor tissue modified viral (TTMV®)-HPV DNA, is in use at leading cancer treatment centers and academic medical centers throughout the United States.

In order to comply with Federal and State tax regulations, please download and complete the below W-9 form from the IRS website. This is required to pay MAPs: Medical Access Points/Providers™ for revenue earned. Once complete, or if you already have a completed W-9 please email to operations@myonemedicalsource.com.